UKI-1 (C007B-432262)

UKI-1 (WX-UK1) is a potent urokinase-type plasminogen activator (uPA) inhibitor with a K i of 0.41 μM. UKI-1 is also a low molecular weight serine protease inhibitor. UKI-1 is a potent antimetastatic agent and inhibits the invasive capacity of carcinoma cellsIn VitroUKI-1 (WX-UK1; 0.1-1.0 μg/mL) treatment shows a decrease of tumor cell invasion by up to 50% is achieved in both models with the SCCHN line FaDu and the cervical carcinoma line HeLa. UKI-1 (WX-UK1) interferes with the plasminogen activation system at 2 levels: it inhibits plasmin formation directly and via inhibition of uPA. In vitro invasion models with highly invasive fibrosarcoma and breast cancer cells showed that UKI-1 effectively inhibits migration of the cells through fibrin matrices. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoUKI-1 (WX-UK1) treatment has antimetastatic activities that significantly reduces the number of metastatic lesions and tumor growth in metastasizing rat pancreatic and mammary adenocarcinoma tumor models . MCE has not independently confirmed the accuracy of these methods. They are for reference only.IC50& Target:Ki: 0.41 μM (Urokinase-type plasminogen activator (uPA)),Serine protease. Specification: 10mM in DMSO Molecular Formula: C32H47N5O5S Molecular Weight: 613.81

UPC:

51112511

Condition:

New

Weight:

1.06 Ounces

HazmatClass:

No

WeightUOM:

LB

MPN:

U656560-1ml

CAS:

220355-63-5

Product Size:

1ml